Clinical trials: Retinal Vein Occlusion With Macular Edema
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Ocular Safety and Usability Study for FYB201 PFS
The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT06708624
- Testing
- FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Formycon AG
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch…
- Trial name
- WAVE (NCT01710839)
- Testing
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Charles C Wykoff, PhD, MD
Non-Ischemic Central Retinal Vein Occlusion With Macular Edema
Ranibizumab Versus Aflibercept for CRVO in Young Patients.
this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old
- Trial name
- NCT05282420
- Testing
- intravitreal injection of Ranibizumab, intravitreal injection of Aflipercept, Ranibizumab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- South Valley University
Macular Edema, Branch Retinal Vein Occlusion
Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
The purpose of this study is to evaluate the efficacy of intravitreal ranibizumab by determining the pathogenesis of macular edema, which cause a direct effect on visual function.
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
- Trial name
- NCT02169648
- Testing
- ranibizumab
- Where
- 2 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Tokyo Medical University
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)…
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07501052
- Testing
- SCD411 0.05mL (2mg)
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab…
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NORSE SEVEN (NCT05112861)
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Outlook Therapeutics, Inc.
Macular Edema Following Branch Retinal Vein Occlusion
Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for macular edema following branch retinal vein occlusion
- Trial name
- NCT01512901
- Testing
- Betamethasone Microsphere (DE-102） Low Dose, Betamethasone Microsphere (DE-102） High Dose
- Where
- 2 sites in Japan, South Korea
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Retinal Vein Occlusion
Ranibizumab in Patients With Branch Retinal Vein Occlusion
In a recent study we could show that the early retinal venous vasoconstriction after grid photocoagulation in branch retinal vein occlusion (BRVO) is closely correlated to the visual outcome after three months.
- Trial name
- NCT01027481
- Testing
- Lucentis
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Macular Edema, Retinal Vein Occlusion
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
- Trial name
- COBALT (NCT01903720)
- Testing
- dexamethasone implant
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Allergan
Diabetic Macular Edema, Branch Retinal Vein Occlusion
Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases
This trial seeks to prove the safety and efficacy of photothermal stimulation treatment to diabetic macular edema, chronic central serous retinopathy, macular edema secondary to branch retinal vein occlusion and macular…
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Chronic Central Serous Retinopathy, Macular Telangiectasia
- Trial name
- EPM (NCT01975103)
- Testing
- Topcon Endpoint Management
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Federal University of Rio Grande do Sul
Retinal Vein Occlusion (RVO), Macular Edema
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
To determine if Ozurdex implant can offer an effective treatment for macular edema associated with retinal vein occlusion when treatment with intravitreal Avastin, Lucentis, or Eylea have not demonstrated a significant response.
- Trial name
- NCT01946399
- Testing
- Ozurdex implant
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Retina Research Institute, LLC
Intraocular Inflammation, Suspected Endophthalmitis
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
Specific study objectives include: To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually).
- Trial name
- NCT05791695
- Testing
- Non Applicable
- Where
- United States
- Volunteers
- 155,413 people
- Sponsor
- Regeneron Pharmaceuticals
Central Retinal Vein Occlusion
Lucentis for Central Retinal Vein Occlusion (CRVO)
The purpose of this study is to determine whether ranibizumab will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
- Trial name
- NCT00406796
- Testing
- Ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- California Retina Consultants
Central Retinal Vein Occlusion With Macular Edema
Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas
The purpose of this study is to determine if additional panretinal photocoagulation of ischemic areas following retinal vein occlusion (RVO) may reduce the rate of recurrence and allow longer treatment intervals in anti-Vascular…
- Trial name
- PEARL (NCT02522897)
- Testing
- Ranibizumab, Laser
- Volunteers
- 60 people
- Sponsor
- PD. Dr. med. Armin Wolf
Branch Retinal Vein Occlusion
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
To compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (601) with Ranibizumab in patients with macular edema secondary to BRVO
- Trial name
- NCT05520177
- Testing
- 601 1.25mg, ranibizumab 0.5mg
- Where
- 10 sites in China
- Volunteers
- 351 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO…
- Trial name
- TOPAZ (NCT03203447)
- Testing
- suprachoroidal CLS-TA, Lucentis or Avastin
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Clearside Biomedical, Inc.
Retinal Vein Occlusion, Macular Edema
Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
This study mainly observed the ischemic index and vascular leakage index changes on ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these changes correlated with treatment efficacy in patients…
- Trial name
- UWFA-RVO-ME (NCT04140448)
- Testing
- Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS], Ultra-wide Fluorescein Angiography
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Renmin Hospital of Wuhan University
Macular Edema, Central Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Trial name
- COMINO (NCT04740931)
- Testing
- Faricimab, Aflibercept
- Where
- 194 sites in United States, Argentina and 20 more
- Volunteers
- 729 people
- Sponsor
- Hoffmann-La Roche